Petros Pharmaceuticals Inc Files For Mixed Shelf Of Up To $100M
Petros Pharmaceuticals Inc Files For Mixed Shelf Of Up To $100M
Petros Pharmaceuticals Announces Online Distribution for Lead ED Product With Lemonaid Health
Petros Pharmaceuticals Announces Online Distribution for Lead ED Product With Lemonaid Health | NASDAQ:PTPI
Petros Pharmaceuticals Expands Online Distribution for Prescription STENDRA(R) (Avanafil) Through New Agreement With Lemonaid Health
Collaboration with leading telemedicine provider to offer marketing and distribution of STENDRA for Lemonaid Health's ED patientsNEW YORK, NY / ACCESSWIRE / April 23, 2024 /
Positive Outlook for Petros Pharmaceuticals: Buy Rating Affirmed Amidst FDA Advances and Promising Stendra Developments
Petros Gets 'Positive' FDA Response Over Technology Component in Stendra OTC Process
Petros Pharmaceuticals (PTPI) said Tuesday it has received "positive" feedback from the US Food and Drug Administration after an informal review of its technology component for self-selection. The com
Petros Pharmaceuticals Receives Response From FDA Following Recent Demonstration Of Technology Component In Pursuit Of OTC Status For STENDRA
Fady Boctor, Petros' President and Chief Commercial Officer, commented, "We view this meeting with the FDA as a significant step in our efforts to move STENDRA to OTC status, a move that would be the first among erectile dysfunction drug manufacturers.
323 drugs, hurry up! America is facing the biggest “drug shortage” in history...
The US now seems to be facing an unprecedented “drug shortage”...
Optimistic Outlook on Petros Pharmaceuticals With a Buy Rating Amid Strategic Shift and Promising Drug Developments
FibroGen, Acorda Therapeutics, Enveric Biosciences Among Healthcare Movers
SOL, MESO and ACOR Among Pre-market Losers
Canopy Growth, Exact Sciences, Stereotaxis Among Healthcare Movers
Petros Pharmaceuticals Reports Positive Results in an Initial Cohort Two-Arm Self-Selection (Phase 2-Equivalent) Study for STENDRA(R) (Avanafil) as It Pursues OTC Status
Nitrate patients subgroup demonstrated 100% correct self-selection when utilizing the web app technology with the drug facts label compared to 40% when using drug facts label alone (among 86% vs. 56%
Petros Pharmaceuticals Q4 EPS $(2.17) Misses $(1.11) Estimate, Sales $364.25K Miss $1.55M Estimate
Petros Pharmaceuticals (NASDAQ:PTPI) reported quarterly losses of $(2.17) per share which missed the analyst consensus estimate of $(1.11) by 95.5 percent. This is a 6.9 percent decrease over losses o
Petros Pharmaceuticals Successfully Launches AI Tool In Collaboration With Multi-Billion-Dollar Software Provider
Petros Pharmaceuticals Partners With AI Firm for New OTC Medication
Petros Pharmaceuticals Enters Into AI Licensing Agreement With Leading Multi-Billion-Dollar Software Provider
AI software expected to further enable Petros's efforts to make STENDRA the first ED product to be offered over the counterNEW YORK, NY / ACCESSWIRE / February 14, 2024 / Petros Pharmaceuticals, Inc.
MQ, ORMP and EXAI Are Among Pre Market Gainers
PLUG, PXLW and ASMB Are Among Pre Market Gainers
Compugen, Iterum Therapeutics Among Healthcare Movers
No Data